Your browser doesn't support javascript.
loading
Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma.
McCarthy, Patrick M; Rendo, Matthew J; Uy, Matthew D; Adams, Alexandra M; O'Shea, Anne E; Nelson, Daniel William; Fenderson, Joshua L; Cebe, Katherine M; Krell, Robert W; Clifton, Guy T; Peoples, George E; Vreeland, Timothy J.
Afiliação
  • McCarthy PM; Department of Surgery, Brooke Army Medical Center, San Antonio, TX, USA.
  • Rendo MJ; Department of Hematology and Oncology, Brooke Army Medical Center, San Antonio, TX, USA.
  • Uy MD; Department of Pathology, Brooke Army Medical Center, San Antonio, TX, USA.
  • Adams AM; Department of Surgery, Brooke Army Medical Center, San Antonio, TX, USA.
  • O'Shea AE; Department of Surgery, Brooke Army Medical Center, San Antonio, TX, USA.
  • Nelson DW; Department of Surgery, William Beaumont Army Medical Center, El Paso, TX, USA.
  • Fenderson JL; Department of Hematology and Oncology, Brooke Army Medical Center, San Antonio, TX, USA.
  • Cebe KM; Department of Pathology, Brooke Army Medical Center, San Antonio, TX, USA.
  • Krell RW; Department of Surgery, Brooke Army Medical Center, San Antonio, TX, USA.
  • Clifton GT; Department of Surgery, Brooke Army Medical Center, San Antonio, TX, USA.
  • Peoples GE; Cancer Vaccine Development Program, San Antonio, TX, USA.
  • Vreeland TJ; Department of Surgery, Brooke Army Medical Center, San Antonio, TX, USA.
Onco Targets Ther ; 14: 3537-3544, 2021.
Article em En | MEDLINE | ID: mdl-34103944
Pancreatic ductal adenocarcinoma (PDAC) remains deadly despite advances in systemic therapies and surgical techniques. While there is increasing utilization of immune therapies across diverse cancer types, PDAC remains generally resistant to these treatments. We report a case of locally advanced PDAC treated with preoperative radiation and anti-PD-1 immunotherapy guided by preoperative PD-L1 tumor analysis. After 4 months of preoperative therapy, the patient was submitted to resection, demonstrating a near-complete pathologic response on final tumor analysis. We will discuss the relevant literature and current state of immunotherapeutics for PDAC.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Onco Targets Ther Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Onco Targets Ther Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos